We use cookies to ensure that we give you the best experience on our website Learn more

Feb 18, 2019

12th International Conference on Advanced Technologies & Treatments for Diabetes

04 - LIRAGLUTIDE-DEGLUDEC FIXED DOSE COMBINATION IMPROVES NASH/NAFLD IN PATIENTS WITH UNCONTROLLED TYPE II DIABETES MELLITUS

liraglutide-degludec fdc

nash

nafld

nash reversibility

Abstract

Abstract

thumbnail

Keywords

liraglutide-degludec fdc

nash

nafld

nash reversibility

Abstract

Objective: Our previous studies have demonstrated that standard treatment of diabetes does not cause significant improvement in NAFLD. Therefore, the present study was conducted to evaluate the effects of Liraglutide-degludec fixed dose combination (FDC) 3.6mg/100 IU on NAFLD with elevated transaminases among patients with T2D. This combination has recently been available in our country. Material and Methods: A total of 34 patients (male-13, female-21) with age group of 35-65 years, uncontrolled with oral anti diabetic drugs and basal insulin were included in the study. These patients had elevated transaminases and NAFLD. Liraglutide-degludec FDC was given along with other oral antidiabetic drugs and standard care. Selected clinical and demographic profile and liver fat content were recorded for all patients at both baseline and 24 weeks of treatment. The hepatic steatosis was assessed using transient elastography (Fibroscan) as CAP value and MR fat quantification. Age, BMI, diabetes duration, FPG, PPG, HbA1c, lipid profile, Microalbuminuria, RFT and LFT were also measured at baseline and every 3 months. All adverse events were recorded. Results: Parameters Baseline Week 24 Change HbA1c (%) 8.6±0.9 7.2±0.6 -1.4% Liver fat content (dB/m) 346.4±38.2 208.3±24 -138.1 Reversibility of transaminases 34/34 27/34 82% Weight (kg) 84.3±8.6 79.1±6.7 -5.2 Conclusion: 1. Liraglutide-degludec FDC is effective for reducing hyperglycemia in uncontrolled diabetes 2. It also reduces hepatic steatosis and effectively cause reversal of elevated transaminases as well as weight reduction 3.We recommend liver histology study for efficacy of this FDC in NASH treatment in T2DM

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.